{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:43:08Z","timestamp":1772620988070,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peroxisomes play essential roles in cellular lipid metabolism and redox regulation, yet their contribution to bladder cancer (BLCA) progression remains poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic and clinical data from TCGA-BLCA and three GEO cohorts were integrated to identify prognostic peroxisome-related genes (PRGs). A six-gene PRG signature was constructed and validated for survival prediction, molecular subtype stratification, and pathway enrichment analyses, with expression validation in bladder cancer cell lines. Drug\u2013gene enrichment and molecular docking were then performed to identify potential therapeutic modulators, which were subsequently assessed using CCK-8 cell viability assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two distinct PRG-based molecular subtypes of BLCA were identified, showing significant differences in survival, mutational landscape, immune infiltration, and metabolic signaling. The high-risk subtype was enriched for PRDX1, ACOX2, and IDI1, reflecting enhanced oxidative stress adaptation and metabolic reprogramming, while the low-risk group was defined by ACSL5 and XDH. Drug-gene enrichment identified erythorbic acid, a redox-active ascorbate analog, as the most biologically relevant compound targeting high-risk PRGs. Molecular docking confirmed stable binding of erythorbic acid to ACOX2 (\u20136.2 kcal\/mol), IDI1 (\u20136.6 kcal\/mol), and PRDX1 (\u20135.4 kcal\/mol) within catalytically active pockets, suggesting coordinated modulation of oxidative metabolism and redox balance. Subsequent CCK-8 assays demonstrated a dose- and time-dependent reduction in viability in bladder cancer cell lines. In contrast, normal urothelial XV-HUC-1 cells showed relatively preserved viability, indicating differential cellular responses to erythorbic acid\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peroxisome-related gene dysregulation shapes the metabolic and immunologic heterogeneity of bladder cancer. Erythorbic acid emerges as a promising redox-metabolic modulator targeting multiple peroxisomal enzymes, offering a potential therapeutic avenue for aggressive, high-risk BLCA subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1734437","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:17Z","timestamp":1772602877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Peroxisomal activity drives aggressive bladder cancer phenotypes and reveals erythorbic acid as a potential therapeutic modulator"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinghui","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Admission Service Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhewen","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Housheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanchang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaocong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Provincial Clinical Medical Center","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3390\/cancers14133181","article-title":"Advances in diagnosis and therapy for bladder cancer","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.7150\/thno.103376","article-title":"Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer","volume":"15","author":"Jiang","year":"2025","journal-title":"Theranostics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3390\/cells10051056","article-title":"Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation","volume":"10","author":"Schiliro","year":"2021","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.04.010","article-title":"Metabolic changes in bladder cancer","volume":"36","author":"Woolbright","year":"2018","journal-title":"Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/cancers16030504","article-title":"Metabolic signature of warburg effect in cancer: an effective and obligatory interplay between nutrient transporters and catabolic\/anabolic pathways to promote tumor growth","volume":"16","author":"Mathew","year":"2024","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","article-title":"Metabolic phenotype of bladder cancer","volume":"45","author":"Massari","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fonc.2018.00333","article-title":"Metabolic plasticity of tumor cell mitochondria","volume":"8","author":"Cannino","year":"2018","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcb.2021.02.005","article-title":"Peroxisomes as cellular adaptors to metabolic and environmental stress","volume":"31","author":"He","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.redox.2019.101167","article-title":"Peroxisomal regulation of redox homeostasis and adipocyte metabolism","volume":"24","author":"Liu","year":"2019","journal-title":"Redox Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/cells9071692","article-title":"Peroxisome metabolism in cancer","volume":"9","author":"Kim","year":"2020","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkp935","article-title":"PeroxisomeDB 2.0: an integrative view of the global peroxisomal metabolome","volume":"38","author":"Schl\u00fcter","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"crossref","first-page":"e57395","DOI":"10.1371\/journal.pone.0057395","article-title":"The proteome of human liver peroxisomes: identification of five new peroxisomal constituents by a label-free quantitative proteomics survey","volume":"8","author":"Gronemeyer","year":"2013","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/jfb5020043","article-title":"HaCaT keratinocytes response on antimicrobial atelocollagen substrates: extent of cytotoxicity, cell viability and proliferation","volume":"5","author":"L\u00f3pez-Garc\u00eda","year":"2014","journal-title":"J Funct Biomater"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1021\/pr9004663","article-title":"Peroxisomes from the heavy mitochondrial fraction: isolation by zonal free flow electrophoresis and quantitative mass spectrometrical characterization","volume":"9","author":"Islinger","year":"2010","journal-title":"J Proteome Res"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.3892\/or.2017.5610","article-title":"Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance","volume":"37","author":"Yen","year":"2017","journal-title":"Oncol Rep"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1111\/imr.12655","article-title":"Fatty acid metabolism in CD8(+) T cell memory: Challenging current concepts","volume":"283","author":"Raud","year":"2018","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1038\/nature08097","article-title":"Enhancing CD8 T-cell memory by modulating fatty acid metabolism","volume":"460","author":"Pearce","year":"2009","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122772","article-title":"Nrf2, the master regulator of anti-oxidative responses","volume":"18","author":"Vomund","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.e10-02-0160","article-title":"Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells","volume":"21","author":"Wang","year":"2010","journal-title":"Mol Biol Cell"},{"key":"B26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12032-014-0455-0","article-title":"Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR\/p70S6K pathway in esophageal squamous cell carcinoma","volume":"32","author":"Gong","year":"2015","journal-title":"Med Oncol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2012.03.103","article-title":"Human peroxiredoxin 1 modulates TGF-\u03b21-induced epithelial-mesenchymal transition through its peroxidase activity","volume":"421","author":"Ha","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2011.4421","article-title":"Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK\/cyclin D1 pathway","volume":"19","author":"Park","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"B29","doi-asserted-by":"crossref","first-page":"e50394","DOI":"10.1371\/journal.pone.0050394","article-title":"Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1\u03b1","volume":"7","author":"Riddell","year":"2012","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0000000000000270","article-title":"Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity","volume":"44","author":"Taniuchi","year":"2015","journal-title":"Pancreas"},{"key":"B31","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.freeradbiomed.2014.10.583","article-title":"Peroxiredoxin 1 knockdown sensitizes cancer cells to reactive oxygen species-generating drugs - an alternative approach for chemotherapy","author":"He","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"e98764","DOI":"10.1371\/journal.pone.0098764","article-title":"Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK\/GCV treatment system","volume":"9","author":"Jiang","year":"2014","journal-title":"PloS One"},{"key":"B33","article-title":"ILK and PRDX1 are prognostic markers in squamous cell\/adenosquamous carcinomas and adenocarcinoma of gallbladder","volume":"34","author":"Li","year":"2013","journal-title":"Tumour Biol"},{"key":"B34","article-title":"Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis","volume":"8","author":"Zhou","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v21.i38.10840","article-title":"Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer","volume":"21","author":"Sun","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B36","article-title":"Oxidative stress-mediated antitumor activity of erythorbic acid in high doses","volume":"3","author":"Miura","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"B37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1541-4337.2004.tb00058.x","article-title":"Reactive oxygen species, aging, and antioxidative nutraceuticals","volume":"3","author":"Lee","year":"2004","journal-title":"Compr Rev Food Sci Food Saf"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2023.10.400","article-title":"The comparison of antioxidant properties and nutrigenomic redox-related activities of vitamin C, C-vitamers, and other common ascorbic acid derivatives","volume":"209","author":"Jakubek","year":"2023","journal-title":"Free Radical Biol Med"},{"key":"B39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41419-022-04725-9","article-title":"Acox2 is a regulator of lysine crotonylation that mediates hepatic metabolic homeostasis in mice","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41419-020-03291-2","article-title":"ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPAR\u03b1 pathway","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.7150\/jca.93832","article-title":"ACOX2 serves as a favorable indicator related to lipid metabolism and oxidative stress for biochemical recurrence in prostate cancer","volume":"15","author":"Tan","year":"2024","journal-title":"J Cancer"},{"key":"B42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12943-025-02420-9","article-title":"ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma","volume":"24","author":"Ye","year":"2025","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the mevalonate pathway in cancer","volume":"7","author":"Juarez","year":"2021","journal-title":"Trends Cancer"},{"key":"B44","doi-asserted-by":"crossref","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","article-title":"The mevalonate pathway, a metabolic target in cancer therapy","volume":"11","author":"Guerra","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e78654","DOI":"10.7554\/eLife.78654","article-title":"Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells","volume":"12","author":"Hart","year":"2023","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201800098","article-title":"Amide neighbouring-group effects in peptides: phenylalanine as relay amino acid in long-distance electron transfer","volume":"19","author":"Nathanael","year":"2018","journal-title":"Chembiochem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2014.01.001","article-title":"Role of glutamate transporters in redox homeostasis of the brain","volume":"73","author":"Robert","year":"2014","journal-title":"Neurochem Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020144","article-title":"Insights into protein-ligand interactions: mechanisms, models, and methods","volume":"17","author":"Du","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1016\/j.gendis.2020.04.010","article-title":"Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma","volume":"9","author":"Qiu","year":"2022","journal-title":"Genes Diseases"},{"key":"B50","doi-asserted-by":"crossref","first-page":"e16874","DOI":"10.7717\/peerj.16874","article-title":"A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma","volume":"12","author":"Gao","year":"2024","journal-title":"PeerJ"},{"key":"B51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12894-024-01404-z","article-title":"Establishment and validation of a novel peroxisome-related gene prognostic risk model in kidney clear cell carcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Urology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2147\/BCTT.S490154","article-title":"A novel peroxisome-related gene signature predicts breast cancer prognosis and correlates with T cell suppression","volume":"16","author":"Wang","year":"2024","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12575-025-00289-y","article-title":"FNDC5 and ACOX1 as biomarkers of peroxisomal activity with contrast outcomes in colon adenocarcinoma","volume":"27","author":"Hepei","year":"2025","journal-title":"Biol Procedures Online"},{"key":"B54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13059-016-0997-0","article-title":"Cross-platform normalization of microarray and RNA-seq data","volume":"17","author":"Thompson","year":"2016","journal-title":"Genome Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13059-024-03159-0","article-title":"Assessing and mitigating batch effects in large-scale omics studies","volume":"25","author":"Yu","year":"2024","journal-title":"Genome Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1734437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:22Z","timestamp":1772602882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1734437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1734437"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1734437","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1734437"}}